A high-risk clinical-stage biopharmaceutical firm with a negative net income of $4.8M in 2024, substantial R&D spending of $2.0M, and minimal revenue from its innovative therapeutic development pipeline.
An investor might consider this stock if they believe the company's proprietary drug discovery platform will successfully advance a candidate into clinical trials or secure lucrative licensing deals. The massive paid-in capital of $251.1M suggests strong historical backing from major partners who may provide future milestone payments to stabilize cash flow. Early-stage biotech stocks offer asymmetric upside potential if the company achieves regulatory approval for any of its therapeutic candidates.
Investors should avoid this stock due to severe liquidity constraints, as current liabilities of $7.0M dwarf the available cash reserves, raising immediate concerns about default or forced asset liquidation. The deteriorating financial trend with increasing annual losses from -$3.6M to -$4.8M indicates that the company is burning through resources without a clear path to profitability. The OTC listing and high debt-to-equity ratio reflect a distressed balance sheet with a negative shareholders' equity of $6.0M, making it an extremely speculative investment.
Provectus Biopharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapeutic programs to treat serious diseases, with recent financial activity centered on research and development expenses. The company operates primarily in the global healthcare market, leveraging its proprietary drug discovery platform to advance candidates through preclinical and clinical trials. With minimal revenue generation and significant cash burn, the business model relies heavily on strategic partnerships, licensing deals, and potential future commercialization of approved products.
In 2024, the company reported a net loss of $4.8M driven by operating expenses totaling $5.1M and research and development costs of $2.0M, resulting in cash flow from operations of -$3.3M. Despite generating minimal revenue of $617K, the firm managed to increase its cash balance slightly to $489K, likely due to a substantial $2.7M inflow from financing activities offsetting operational drains. The financial health is precarious with current liabilities significantly outpacing current assets, signaling potential solvency challenges in the near term.
The biopharmaceutical industry is characterized by high barriers to entry, long development cycles, and significant regulatory oversight from agencies like the FDA and EMA. Companies in this sector often operate at a loss during clinical phases, relying on external funding until a product reaches commercialization. Success depends on scientific innovation, robust clinical trial execution, and the ability to navigate complex patent landscapes to maintain market exclusivity.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $989.0K | $557.7K | $617.1K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $989.0K | $557.7K | $617.1K |
| Operating Expenses | $4.4M | $3.5M | $5.1M |
| Operating Income | $-3.4M | $-2.9M | $-4.5M |
| R&D | $2.4M | $1.7M | $2.0M |
| G&A | $2.0M | $1.7M | $3.2M |
| Stock-Based Comp | $3.0K | $2.9K | $1.3M |
| Depreciation | $10.9K | $8.9K | $7.2K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $-126.7K | $-224.7K | $-229.8K |
| Interest Expense | — | $5.7K | $13.6K |
| Pre-Tax Income | $-3.6M | $-3.1M | $-4.8M |
| Income Tax | $0 | $-24.2K | $0 |
| Continuing Ops | $-3.6M | $-3.1M | $-4.8M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-3.6M | $-3.1M | $-4.8M |
| Minority Interest | $0 | $0 | $-29.6K |
| Net to Common | $-3.6M | $-3.1M | $-4.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $1.9M | $1.4M | $976.8K |
| Cash & Equivalents | $21.6K | $76.6K | $307.4K |
| Prepaid Expenses | — | $337.5K | $487.0K |
| Other Current Assets | $1.9M | $950.7K | $182.3K |
| Long-Term Assets | $138.1K | $84.0K | $29.5K |
| PP&E (Net) | $20.9K | $12.0K | $4.9K |
| Operating Leases | $117.1K | $72.0K | $24.6K |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $2.0M | $1.4M | $1.0M |
| Current Liabilities | $8.2M | $9.0M | $7.0M |
| Accounts Payable | $2.1M | $1.7M | $1.1M |
| Current Leases | $44.4K | $48.1K | $25.3K |
| Other Current Liab | $6.1M | $7.3M | $5.8M |
| Long-Term Liabilities | $73.4K | $25.3K | $0 |
| LT Operating Leases | $73.4K | $25.3K | — |
| Other LT Liab | $0 | $0 | — |
| Total Liabilities | $8.3M | $9.0M | $7.0M |
| Shareholders' Equity | $-6.2M | $-7.6M | $-6.0M |
| Paid-In Capital | $243.0M | $244.7M | $251.1M |
| Retained Earnings | $-249.6M | $-252.7M | $-257.4M |
| AOCI | $-35.7K | $-60.2K | $-60.7K |
| Total L&E | $2.0M | $1.4M | $1.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-3.6M | $-3.1M | $-4.8M |
| Non-Cash Adjustments | $321.6K | $959.6K | $1.5M |
| Working Capital Changes | $191.6K | $-429.8K | $-26.7K |
| Cash from Operations | $-3.0M | $-2.6M | $-3.3M |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $1.4M | $2.2M | $2.7M |
| FX Effect | $-1.6K | $-24.5K | $-847 |
| Net Change in Cash | $-1.7M | $-404.9K | $-537.1K |
| Beginning Cash | $3.1M | $1.4M | $1.0M |
| Ending Cash | $1.4M | $1.0M | $489.7K |
The company's financial profile indicates a single primary business segment dedicated to early-stage drug discovery and development, evidenced by significant research and development expenditures ($2.0M) and general administrative costs ($3.2M) with negligible cost of revenue. Revenue is generated through licensing agreements, collaboration milestones, and royalties rather than direct product sales, typical for pre-commercial biotech entities.
The company faces significant liquidity risk with current liabilities of $7.0M far exceeding cash and equivalents of approximately $489K, creating an urgent need for additional capital or financing. Operational risk is high due to a history of negative net income trends worsening from -$3.6M in 2022 to -$4.8M in 2024, indicating unsustainable burn rates without successful product approvals. Regulatory approval uncertainty poses a threat as clinical trial failures could render current R&D investments worthless. Market volatility and dilution risks are elevated given the paid-in capital of $251.1M paired with a massive retained earnings deficit of -$257.4M.
The company possesses a proprietary drug discovery platform that aims to accelerate the identification of novel therapeutic targets for unmet medical needs. Its strategic asset-light model allows it to focus capital on high-potential clinical candidates while minimizing overhead through partnerships and licensing rather than manufacturing infrastructure. A dedicated team of scientific experts provides deep domain knowledge in oncology and other therapeutic areas, enhancing the probability of successful clinical outcomes.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.